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pc-Jun predicts oral cancer prognosis
Background: Overexpression or activation of c-Jun has been implicated in the pathogenesis of several types
of cancer. Treatment of oral cells with areca nut extract in culture can increase c-Jun proto-oncogene mRNA
levels. The purpose of this study was to investigate the possible role of c-Jun activation in the pathogenesis
and prognosis of areca quid chewing-related oral cancer in Taiwan.
Methods: We immunohistochemically examined c-Jun protein activation in human oral squamous cell
carcinomas (SCC) using an anti-phosphospecific c-Jun (pc-Jun) antibody on paraffin-embedded sections.
Results: Positive pc-Jun staining was observed in 42 of 70 (60%) cases of oral SCC. No significant correlation
was found between pc-Jun expression and patients’ age, gender, oral habit, cancer location, clinical stage,
tumor size and lymph node status. Kaplan-Meier curves showed that oral SCC patients with positive pc-Jun
staining or positive lymph node metastasis had significantly shorter overall survival (p < 0.018 and 0.001,
respectively, by log-rank test).
Conclusion: These results indicate that c-Jun activation may play an important role in the carcinogenesis of
oral SCC. Positive pc-Jun staining may serve as an adjuvant marker of worse prognosis in patients with oral
SCC in Taiwan. [J Formos Med Assoc 2006;105(3):229–234]
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The chewing of areca nut (Areca catechu), also
called betel nut, preparations has long been as-
sociated with the high incidence of oral submu-
cous fibrosis and oral cancer in India and many
Southeast Asian countries.1 In Taiwan, approxi-
mately 2 million people have an areca quid (AQ)
chewing habit.2 The ingredients and method
used to make AQ in Taiwan differ from that used
in other parts of the world; most chewers con-
sume AQ that is made by cutting the fresh areca
nut into halves and sandwiching between a
piece of Piper betle (PB) inflorescence with lime
mixture, with or without PB leaf. No tobacco is
added to the quid. This chewing habit is also a
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significant risk factor for malignant transforma-
tion from leukoplakia to oral carcinoma after ad-
justment for other relevant risk factors, whereas the
effect of smoking on malignant transformation is
not significant.3
Recently, we found that treatment of oral mu-
cosal cells with areca nut extract or arecoline in
culture induced a threefold increase in c-Jun
proto-oncogene mRNA levels.4 The c-Jun gene en-
codes a 39 kDa nuclear protein that is a major com-
ponent of the mammalian transcription factor acti-
vator protein-1 (AP-1) and is involved in cellular
proliferation, transformation and apoptosis.5,6
The activity of c-Jun protein is positively regulated
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node was found to be positive for SCC, neck dis-
section and postoperative radiation therapy were
also included in the treatment protocol. None of
the patients had received cancer therapy before
their initial biopsies. Details of the patients’ oral
habits, including daily consumption of AQ and
cigarettes as well as the duration of these habits,
were also recorded. Ten biopsy specimens of nor-
mal oral mucosa (NOM) were obtained from 10
non-AQ-chewers during extraction of impacted
permanent lower third molars after obtaining in-
formed consent, and used as the controls.
Immunohistochemical staining was performed
using a streptavidin-biotin immunoperoxidase
technique as previously described.16 Briefly, sec-
tions were deparaffinized and then treated with
3% H2O2 to remove endogenous peroxidase acti-
vity. After blocking nonspecific binding with 10%
normal goat serum (Zymed Laboratories, San
Francisco, CA, USA), sections were incubated with
mouse monoclonal anti-human phosphospecific
c-Jun (Ser63) antibody (pc-Jun; KM-1, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) overnight at
4°C. According to the manufacturer’s instructions,
this antibody can be used for detection of c-Jun
p39 phosphorylated on serine-63 of mouse and
human origin by Western blot, immunoprecipi-
tation and immunostaining of formalin-fixed,
paraffin-embedded cancer specimens.17,18 No cross-
reaction with Jun-B or Jun-D phosphorylated on
the analogous serine residues or with c-Jun non-
phosphorylated at serine-63 was detected. Bound
antibodies were detected by sequential incuba-
tions with biotinylated goat anti-mouse IgG anti-
body, streptavidin-peroxidase conjugate and dia-
minobenzidine (Zymed). The sections were then
counterstained with hematoxylin and examined
by light microscopy. The primary antibody was re-
placed by non-immune mouse serum as a nega-
tive control.
Specimens were examined under a light micro-
scope and epithelial nuclear staining was counted.
The grade of pc-Jun expression in each specimen
was evaluated according to the percentage of posi-
tively stained cells among the total number of
counted cancer or epithelial cells. Although there
by N-terminal phosphorylation at serines 63 and
73 (Ser63/73),7 and can positively regulate cell
proliferation through the repression of tumor
suppressor gene p53 expression and induction of
cyclin D1 transcription.5 In human malignancies,
c-Jun overexpression or activation has been found
in a wide variety of human tumors, including
liver,8 non-small cell lung,9 endometrial,10 head
and neck,11,12 pancreatic,13 breast14 and oral can-
cers.15 In addition, high levels of c-Jun expression
or activation have been associated with poor prog-
nosis in non-small cell lung,9 breast,14 endometri-
al10 and pancreatic cancers.13 However, no previous
study on the relationship between c-Jun expression
or activation and overall patient survival in oral
squamous cell carcinomas (SCC) has been re-
ported.
We previously showed that overexpression
of cyclin D1 occurred in 83% of oral SCC and was
associated with poor prognosis.16 The transcrip-
tional activation of c-Jun by areca nut extract and
overexpression of cyclin D1 in oral SCC led us to
postulate that c-Jun may also play a role in the
pathogenesis of oral SCC. In this study, we used
an immunohistochemical technique to investigate
c-Jun activation in oral SCC. The immunostaining
results were further correlated with clinicopatho-
logic characteristics of the tumors and patient
survival to investigate a possible influence of c-Jun
activation on the progression and prognosis of
oral SCC in Taiwan.
Methods
Formalin-fixed, paraffin-embedded specimens
from 70 patients (63 men, 7 women) with prima-
ry oral SCC were included in this study. Diagnosis
was made by histologic examination of oral lesions
on hematoxylin and eosin-stained slides. All pa-
tients received total surgical excision of the can-
cers at the Department of Oral and Maxillofacial
Surgery, National Taiwan University Hospital,
Taipei, Taiwan, between 1996 and 2002; speci-
mens were obtained from incisional biopsies or
total surgical excision of the lesions. If a lymph
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was variability in the total number of cells count-
ed in each specimen, the percentage of positively
stained cells was estimated by counting 300 cells
per area from five varied areas and represented as
labeling indices (LI). The tumor specimens were
considered positive for pc-Jun expression when
more than 10% of tumor cells were stained. The
correlation between pc-Jun expression and clini-
copathologic parameters of oral SCC was analyzed
by Fisher’s exact test using SAS version 8.0 (SAS
Institute Inc, Cary, NC, USA). Cumulative survival
was analyzed with the Kaplan-Meier product-limit
method. The duration of survival was measured
from the beginning of treatment to the time of
death or the last follow-up. Comparison of cumu-
lative survival between groups was performed
using the log-rank test with the Statistica program
(StatSoft Inc, Tulsa, OK, USA).
Results
To investigate the impact of c-Jun activation in oral
SCC, immunohistochemical analysis was per-
formed using an anti-pc-Jun antibody on paraffin-
embedded sections. Typical staining patterns for
pc-Jun are shown in Figure 1. In oral SCC, positive
pc-Jun staining was mainly nuclear and found
evenly in tumor epithelial cells (Figure 1A) and
occasionally in associated stromal cells. In NOM,
most cases showed negative pc-Jun staining (Fig-
ure 1B), whereas positive staining was detected
in a few basal epithelial cells (mean LI = 5.5 ±
1.5%) in four cases. Therefore, we used 10%
(approximately mean ± 2 SD) as the cut-off value
to differentiate positive versus negative c-Jun
activation for subsequent analyses, and found
c-Jun activation in 42 of 70 (60%) cases of oral
SCC.
The relationships between pc-Jun LI in speci-
mens of oral SCC and clinicopathologic parame-
ters of 70 oral SCC patients are shown in the Table.
No significant correlation was found between
pc-Jun LI and age, gender, cancer location, clinical
staging, primary tumor TNM status, AQ chewing
or smoking habits, or histologic differentiation of
SCC at the time of initial presentation (p > 0.05).
Kaplan-Meier analysis showed that patients with
tumors containing > 10% pc-Jun-positive cells had
significantly shorter overall survival than those with
tumors containing ) 10% (p < 0.018, Figure 2A).
Patients with positive lymph node status also had
significantly shorter overall survival (p < 0.001, Fig-
ure 2B).
Discussion
de Sousa et al used non-phosphorylated c-Jun
polyclonal antibody to investigate c-Jun expression
in NOM and oral SCC, and found that c-Jun was
detected in the cytoplasm of suprabasal cells in
NOM, while in oral SCC, c-Jun was detected in
all the nuclei of the cancer cells.15 It has been re-
ported that phosphorylation of c-Jun is the key
event in the control of AP-1 activity.7 Therefore,
we used a phosphospecific c-Jun antibody to in-
vestigate c-Jun activation in oral SCC, which was
positive in 60% of cases. These results indicate
that there is a pool of total c-Jun in oral SCC, and
Figure 1.
Typical staining
patterns for
pc-Jun:
(A) normal
buccal mucosa
showing
negative pc-Jun
staining in all
epithelial cells
(× 100);
(B) well-
differentiated
oral squamous
cell carcinoma
showing
positive pc-Jun
nuclear staining
in about 80%
of cancer cells
(× 100).
  A
  B
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that a substantial proportion of this protein is in
an active, serine 63-phosphorylated state.
Extracellular signals including growth factors
(e.g. epidermal growth factor and transforming
growth factor-_), transforming oncoproteins (e.g.
Ha-ras, raf-1, c-sis), cytokines and UV have been
shown to stimulate c-Jun phosphorylation at
Ser63/73 and activate c-Jun-dependent tran-
scription.7 In the case of cell transformation, over-
expression of c-Jun can lead to malignant transfor-
mation of immortalized rat fibroblasts while
transformation of rat embryo fibroblasts by c-Jun
requires cooperation with activated ras.19 This on-
cogenic cooperation is partially dependent on c-
Jun phosphorylation at Ser63/73.20 Young et al
showed that transgenic mice expressing c-Jun
dominant-negative mutant (TAM67) are resistant
to DMBA-TPA-induced skin papillomagenesis
without evidence of skin anomalies.21 Further-
more, skin tumor development caused by consti-
tutive activation of the ras pathway was impaired
in Ser63/73 mutant mice, supporting the signifi-
cance of c-Jun phosphorylation in ras-induced
carcinogenesis.22 We previously showed that mu-
tations and overexpression of ras oncogenes are
important in the oncogenesis of AQ chewing-
related human oral SCC in Taiwan.23,24 Therefore,
the co-activation of c-Jun and ras may play an im-
portant role in the pathogenesis of oral SCC in
Taiwan.
It has been shown that c-Jun overexpression
increased expression of a matrix-degrading en-
zyme MMP-9 and in vitro chemoinvasion in MCF7
breast cancer cells.25 Furthermore, stable expres-
sion of TAM67 mutant can effectively inhibit 12-
O-tetradecanoylphorbol-13-acetate-induced inva-
sion in mouse keratinocytes.26 A relationship be-
tween c-Jun expression and an invasive/metastatic
potential has also been noted for several human
tumors. Yokoyama et al showed that c-Jun expres-
sion was related to lymph node metastasis in en-
dometrial carcinomas.10 Volm et al found that c-Jun
overexpression in primary lung carcinomas was
significantly correlated to lymph node involve-
ment.27 Tiniakos et al showed that the intensity of
c-Jun immunostaining was significantly related to
tumor stage in transitional cell carcinomas (TCC)
of the urinary bladder and found a positive associ-
ation between an intense c-Jun immunoreactivity
and muscle invasive growth.28 Furthermore, Gee
et al found that increased c-Jun activation in hu-
man breast cancer was significantly associated
with distant metastasis.14 In contrast, Nephew et
al showed that expression of c-Jun does not cor-
Table. Correlation between pc-Jun expression in oral squamous
cell carcinoma (SCC) and the clinicopathologic
parameters of 70 oral SCC patients
Degree of c-Jun staining
p
0–10% 11–50% * 51%
Age (yr) 0.866
< 40 2 2 3
40–49 8 3 6
50–59 9 7 4
60–69 8 8 6
* 70 1 2 1
Gender 0.787
Male 250 190 190
Female 3 3 1
Cancer location 0.379
Buccal mucosa 100 9 120
Gingiva 5 1 2
Tongue 8 6 4
Palate 1 4 0
Oropharynx 4 2 2
Clinical stage 0.243
1 4 4 6
2 120 6 2
3 4 4 2
4 8 8 100
T status 0.516
T1 5 5 9
T2 140 110 7
T3 2 1 0
T4 7 5 4
Lymph node involvement 0.852
Yes (N1 + N2 + N3) 8 8 7
No (N0) 200 140 130
Oral habit 0.512
AQ chewer and smoker 210 150 140
AQ chewer only 1 0 0
Smoker only 1 3 4
Non-AQ chewer and nonsmoker 5 4 2
AQ = areca quid.
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relate with endometrial cancer stage and grade.29
In the present study, no significant correlation
was found between the LI of pc-Jun and patients’
STNM status. In addition, the LI of pc-Jun was
found at a similar level in both early and advanced
stages of oral SCC. Thus, c-Jun activation may be
an early event in oral carcinogenesis.
It has been shown that patients with non-small
cell lung,9 breast,14 endometrial10 and pancreatic
cancers13 exhibiting c-Jun overexpression or acti-
vation have a poor prognosis. However, some
studies found no significant correlation between
c-Jun expression and overall survival in patients
with hepatocellular carcinoma,8 non-small cell
lung cancer,27 or TCC of the urinary bladder.28 In
head and neck SCC, Riva et al showed that over-
expression of c-Jun is associated with the absence
of tumor response to neoadjuvant chemotherapy
or radiotherapy and with tumor relapse, but fails
to predict patients’ long-term survival.11 Miura et
al assessed c-Jun expression in head and neck SCC
after radiation therapy and found that c-Jun ex-
pression in residual or relapse tumors was higher
than in tumors showing complete regression.12 This
study showed that patients with tumors contain-
ing > 10% pc-Jun-positive cells had significantly
shorter overall survival. Thus, pc-Jun positive stain-
ing may serve as an adjuvant marker of poor sur-
vival in patients with oral SCC in Taiwan.
In conclusion, this study demonstrated a high
incidence of c-Jun activation in oral SCC in Taiwan.
Furthermore, c-Jun activation correlated with poor
overall survival. To our knowledge, this is the first
study to show that c-Jun activation correlates with
overall survival in patients with oral SCC. We sug-
gest that c-Jun activation may be included with
other prognostic factors used to characterize sub-
sets of oral SCC patients with a poor outcome, and
that c-Jun antagonists such as curcumin30 may have
a role in the chemoprevention and therapy of oral
cancer.
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